Skip to content

The Effects of Dietary Fiber-Enriched Complete Nutritional Diet on Intestinal Immune Activation and Visceral Fat.

The Effects of Dietary Fiber-Enriched Complete Nutritional Diet on Intestinal Immune Activation and Visceral Fat. - The Effects of Dietary Fiber-Enriched Complete Nutritional Diet on Intestinal Immune Activation and Visceral Fat.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000047873
Enrollment
40
Registered
2023-06-07
Start date
2022-10-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Oral intake of test meal A (4 times in a day [eating for breakfast, lunch, dinner, and snacks
4 weeks.). Oral intake of normal meals (keeping habit of eating before participating with the study
4 weeks).

Sponsors

NISSIN FOOD PRODUCTS CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: [1] Healthy Japanese males aged 30-64 years. [2] Individuals whose visceral fat area is over 100cm2. [3] Individuals who do not have a habit of drinking. [4] Individuals whose written informed consent has been obtained. [5] Individuals who can visit an inspection facility and be inspected in designated days. [6] Individuals judged appropriate for the study by the principal.

Exclusion criteria

Exclusion criteria: [1] Individuals who cannot continue to eat a test meal for 4 weeks. [2] Individuals whose eating habit for breakfast, lunch, and dinner is irregular and has an unbalanced diet. [3] Individuals who are in constipation. [4] Individuals using medical products. [5] Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. [6] Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. [7] Individuals who have a history of serious hepatopathy, kidney damage, heart disease, hematological and blood disease. [8] Individuals who contract or have a history of serious endocrine disease. [9] Individuals with metal in their body that cannot be removed. Individuals with a cardiac pacemaker. [10] Individuals who recorded weight gain and loss (+-2 kg) in the past 1 month. [11] Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months. [12] Individuals who are sensitive to test product or other foods, and medical products. [13] Individuals who are undergoing dietary therapy [14] Individuals with possible changes of life style, such as conducting a long-term travel, during the test period. [15] Individuals who have or had a habit to ingest health-promoting foods, foods for specified health uses, or health foods in the past 3 months, or will ingest those foods during the test period. [16] Individuals who have difficulty conducting tests using mobile applications. [17] Individuals who are unable to properly store or consume the test foods due to reasons such as inability of setting the distributed freezer or non-possession of a microwave oven. [18] Individuals who participated in other clinical studies in the past 3 months. [19] Individuals who are or whose family is engaged in health foods of functional foods. [20] Individuals judged inappropriate for the study by the principal.

Design outcomes

Primary

MeasureTime frame
[1] Indexes for visceral fat area and genetic analysis.

Secondary

MeasureTime frame
*Secondary indexes [1] Specific fecal test [2] Specific blood test [3] Indexes for body composition. [4] Physical and clinical examinations. [5] Measurement of subcutaneous fat area by FatScan using CT scan images. [6] Food frequency questionnaire:FFQ *Safety [1] Doctor's questions [2] Side effects and adverse events [3] Subject's diary *Other indexes [1] Evaluation of visceral fat mass area by impedance method.

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings Co., Ltd. Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp+81-3-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026